Skip to main content
SpringerLink
Log in

Vax combating MenB shows potential for routine immunisation

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vesikari T, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet : 14 Jan 2013. Available from: URL: http://dx.doi.org/10.1016/S0140-6736%2812%2961961-8.

    PubMed  Google Scholar 

  2. Snape MD, et al. The beginning of the end for serogroup B meningococcus? Lancet : [2 pages], 14 Jan 2013. Available from: URL: http://dx.doi.org/10.1016/S0140-6736(12)62194-1.

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vax combating MenB shows potential for routine immunisation. Reactions Weekly 1436, 4 (2013). https://doi.org/10.1007/s40278-013-0864-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-013-0864-4

Search

Navigation